LEON's FR-JET Technology Validated for Advanced Nanoparticle Manufacturing

leon-nanodrugs GmbH, a German Pharmatech company, has successfully concluded a feasibility study in collaboration with Evonik Canada Inc. The study confirmed the performance of LEON’s FR-JET technology for manufacturing nanoparticles used in drug delivery. This validation highlights FR-JET's efficiency, precision, and consistency in producing high-quality nanoparticles.

The study involved creating various drug-loaded and placebo nanoparticles using lipid and polymer-based systems. It demonstrated FR-JET's versatility and scalability, beneficial for both research and commercial production. This aligns with the growing demand for versatile manufacturing platforms to support the diversity of active pharmaceutical ingredients and delivery systems.

The results pave the way for advancements in drug delivery, especially crucial for the progress of cell and gene therapies. Dr. Setu Kasera, LEON's Chief Scientific Officer, expressed enthusiasm about the technology's validation, noting its potential to enhance drug performance and streamline production processes.